Patents Examined by Christina Chan
-
Patent number: 7332168Abstract: The present invention relates to a composition for the selective elimination of autoreactive B-cells comprising at least one (poly)peptide construct consisting of at least two domains wherein one of said domains comprises an autoreactive antigen or (a) fragments(s) thereof specifically recognized by the Ig receptors of said autoreactive B-cells and wherein one of said domains comprises an effector molecule capable of interacting with and/or of activating NK-cells, T-cells, macrophages, monocytes and/or granulocytes and/or capable of activating the complement system.Type: GrantFiled: August 22, 2001Date of Patent: February 19, 2008Assignee: Micromet AGInventors: Marcel Zocher, Patrick Bäeuerle, Torsten Dreier
-
Patent number: 7332579Abstract: The present invention concerns isolated antibodies that specifically bind to the human ErbB4 of SEQ ID NO:2, as well as humanized antibodies, human antibodies and antibody fragments, as well as bispecific antibodies capable of binding both the human ErbB4 of SEQ ID NO:2 and ErbB3. The invention further concerns antibodies which specifically bind to human ErbB4 of SEQ ID NO: 2 with a Kd less than 100 nM, antibodies which specifically bind to human ErbB4 of SEQ ID NO: 2 and which reduces heregulin binding thereto, and antibodies which specifically bind to human ErbB4 of SEQ ID NO: 2 and which reduce heregulin-induced tyrosine phosphorylation thereof.Type: GrantFiled: August 29, 2001Date of Patent: February 19, 2008Assignee: Genentech, Inc.Inventors: Mary E. Gerritsen, Mark X. Sliwkowski
-
Patent number: 7326767Abstract: A peptide comprising the amino acid sequence RMFPNAPYL (SEQ ID NO:1) or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence CMTWNQMNL (SEQ ID NO:2) or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence HLMPFPGPLL (SEQ ID NO:3) or a portion or variant thereof provided that the peptide is not intact human gata-1 polypeptide, and polynucleotides encoding these peptides. The peptides and polynucleotides are useful as cancer vaccines.Type: GrantFiled: July 26, 2000Date of Patent: February 5, 2008Assignee: Ganymed Pharmaceuticals, AGInventors: Hans Josef Stauss, Liquan Gao
-
Patent number: 7320873Abstract: The invention describes a method to diagnose the autoimmune disease activity by detecting the presence of an autoimmune specific MHC-peptide complex in a patient suffering from an autoimmune disease. The MHC-peptide complex is associated with rheumatoid arthritis. Monoclonals antibodies to be used for this method are also described. The antibodies can also be used for therapeutic purposes.Type: GrantFiled: August 8, 2001Date of Patent: January 22, 2008Assignee: N.V. OrganonInventor: Petrus Gerardus Antonius Steenbakkers
-
Patent number: 7320870Abstract: The present invention relates to a novel lacrimal gland protein (designated lacritin) and the nucleic acid sequences encoding that protein. Lacritin has activity as a growth factor on both human corneal epithelial cells and on the lacrimal acinar cells that produce it. Accordingly, one embodiment of the present invention is directed to the use of lacritin to treat Dry Eye and other disorders requiring the wetting of the eye.Type: GrantFiled: March 6, 2007Date of Patent: January 22, 2008Assignee: University of Virginia Patent FoundationInventors: Gordon W. Laurie, Sandhya Sanghi, Kumar Rajesh, Angela J. Lumsden
-
Patent number: 7320786Abstract: This invention discloses methods, kits, and instructions to treat neovasculature diseases of the eye through the administration of a targeted photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate photosensitizing agent. The photosensitizing agent is bound to a composition that mediates site specific delivery to a neovasculature target tissue of a therapeutically effective amount of a photosensitizing agent that is activated by a relatively low fluence rate of light over a prolonged period of time. Diseases treatable under this invention, include: diabetic retinopathy; macular degeneration; and malignant uveal melanomas.Type: GrantFiled: December 7, 2005Date of Patent: January 22, 2008Assignee: Light Sciences Oncology, Inc.Inventor: James C. Chen
-
Patent number: 7319143Abstract: The invention provides DNA molecules encoding a chimeric polypeptide comprising (a) a component of a MHC molecule capable of association on a cell surface with an endogenous MHC molecule component of the same class, and (b) an intracellular region of a signal transduction element capable of activating T cells. Component (a) may be a monomorphic component and is preferably beta 2-microglobulin, or a polymorphic class I or class II component. The signal transduction element (b) capable of activating T cells may be a component of T-cell receptor CD3, preferably the CD3 zeta (zeta) polypeptide, a B cell receptor polypeptide or an Fc receptor polypeptide. Immune cells such as a CTLs expressing said chimeric MHC molecules specifically eliminate or inactivate harmful T cells and are useful for treating graft rejection and autoimmune diseases.Type: GrantFiled: May 31, 2001Date of Patent: January 15, 2008Assignee: Gavish-Galilee Bio Application Ltd.Inventors: Gideon Gross, Alon Margalit
-
Patent number: 7319019Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Also included is the mature GGF peptide and the DNA encoding said peptide, exclusive of the N-terminal signal sequence. The mature GGF peptide and DNA encoding the same are also useful for treatment of conditions of the central nervous system. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.Type: GrantFiled: October 22, 1996Date of Patent: January 15, 2008Assignees: Acorda Therapeutics, Inc., Ludwig Institute for Cancer ResearchInventors: Andrew David Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchionni, Maio Su Chen, Ian Hiles
-
Patent number: 7314621Abstract: Antibodies that specifically bind to AID (Activation-Induced cytidine Deaminase) proteins, compositions comprising said antibodies, and cells producing said antibodies, are described. The AID proteins are structurally related to APOBEC-1,l an RNA editing enzyme, and have a cytidine deaminase activity similar to APOBEC-1. The AID genes were found by preparing cDNA libraries from mouse B cell clone CH12F3-2 (which undergoes class switch recombination from IgM to IgA at an extremely high rate after activation of the cells by stimulation with cytokines), with and without stimulation with cytokines, and performing subtraction cloning using the libraries.Type: GrantFiled: July 11, 2006Date of Patent: January 1, 2008Assignee: Kyoto UniversityInventors: Tasuku Honjo, Masamichi Muramatsu
-
Patent number: 7312025Abstract: A cell culture system related to extended in vitro culture of mature neuronal cells and methods for preparing the cell culture system are provided. In a preferred embodiment the invention provides a cell culture system comprising a mixture of mature neuronal retinal cells and cells isolated from a ciliary body. Methods for identifying bioactive agents that alter neurodegeneration of neuronal retinal cells are also provided.Type: GrantFiled: July 11, 2003Date of Patent: December 25, 2007Assignee: University of WashingtonInventors: Ryo Kubota, Thomas A Reh, Andrew J Fischer
-
Patent number: 7311892Abstract: Described is a multi drug multiligand conjugate for targeted drug delivery. The MDML conjugate contains a plurality of tripartite molecules linked to a central scaffold moiety, with each tripartite molecule comprising a targeting molecule, a therapeutic agent and a scaffold binding element. The MDML conjugate allows for more efficient delivery of therapeutic agents to the cells resulting in enhanced therapeutic efficiency. A model MDL conjugate is disclosed as well as method for the synthesis of the model conjugate.Type: GrantFiled: October 28, 2002Date of Patent: December 25, 2007Assignee: The UAB Research FoundationInventor: Ahmad Safavy
-
Patent number: 7306782Abstract: The present invention relates to a method for the preparation of a conjugate comprising a first and a second polypeptide, said method comprising the steps of (a) incubating said first polypeptide in the presence of a heterobifunctional crosslinker comprising an N-hydroxylsuccinimide ester group and a maleimide group linked via a polyethylene oxide spacer; (b) removing excess heterobifunctional crosslinker; and (c) incubating the reaction product of step (b) with said second polypeptide, wherein said second polypeptide comprises at least one sulfhydryl group. Furthermore, the present invention relates to a conjugate obtainable by the method of the present invention. Also described is a pharmaceutical composition comprising the conjugate of the present invention and, optionally, a pharmaceutically acceptable carrier and/or diluent, and the use of the conjugate for the preparation of a pharmaceutical composition for preventing and/or treating an allergic disease or an autoimmune disease.Type: GrantFiled: February 14, 2003Date of Patent: December 11, 2007Assignee: Tolerogen LtdInventors: Yves Borel, Werner Schlegel, Erwin Gelfand
-
Patent number: 7306803Abstract: Recombinant plasminogen activator inhibitor-1 (PAI-1) isoforms which lack the reactive center loop and contain the complete heparin-binding domain or lack at least a portion of the heparin-binding domain are described. The rPAI-1 isoforms disclosed herein may be used to modulate angiogenesis through blocking release of VEGF from a VEGF-heparin complex. Furthermore, the rPAI-1 proteins may be used to inhibit cell proliferation and migration, induce apoptosis, and produce proteolytic fragments corresponding to angiostatin kringles 1-3 and kringles 1-4. A truncated proteolytic plasmin protein of 34 kDa is also provided.Type: GrantFiled: April 13, 2006Date of Patent: December 11, 2007Assignee: Trustees of Dartmouth CollegeInventor: Mary Jo Mulligan-Kehoe
-
Patent number: 7304029Abstract: The invention relates to neuroprotection and to medicaments for use therein. Neuroprotection is induced by activation of neural growth hormone receptors, primarily using medicaments comprising growth hormone, growth hormone analogs or ligands which are functionally equivalent. Such medicaments may also include one or more secondary neuroprotective agents.Type: GrantFiled: September 3, 1999Date of Patent: December 4, 2007Assignee: Neuren Pharmaceuticals Ltd.Inventors: Arjan Scheepens, Christopher E. Williams, Peter David Gluckman, Ross Graham Clark
-
Patent number: 7300652Abstract: Disclosed are antibodies that inhibit proteolytic release of a soluble KIM-1 polypeptide from KIM-1 expressing cells. Also disclosed are methods of using the antibodies to inhibit shedding of the KIM-1 polypeptide.Type: GrantFiled: February 7, 2006Date of Patent: November 27, 2007Assignees: Biogen Idec MA Inc., The General Hospital CorporationInventors: Veronique Bailly, Joseph Bonventre
-
Patent number: 7294477Abstract: The present invention is related to novel nucleoli sequences encoding a louse allergen and a methods for diagnosing, treating and preventing lice infestation and associated allergic disease with the nucleoli sequences and protein allergen of the invention. The present invention also relates to kits for diagnostic assays.Type: GrantFiled: April 19, 2001Date of Patent: November 13, 2007Assignee: Ovita LimitedInventors: Alexander Terrance Pfeffer, Charles Bix Shoemaker
-
Patent number: 7294473Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.Type: GrantFiled: November 25, 2003Date of Patent: November 13, 2007Assignee: Japan Tobacco Inc.Inventors: Takuya Tamatani, Katsunari Tezuka
-
Patent number: 7291336Abstract: Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand functionally linked to an immunogen, e.g. tumor associated antigens, bacterial or viral antigens, etc. Methods are disclosed for delivery of these molecular adjuvants to patients, resulting in the transduction of activating signals to the targeted antigen presenting cell, thereby enhancing the immune response to the co-delivered immunogen.Type: GrantFiled: May 28, 2004Date of Patent: November 6, 2007Assignee: Board of Regents of the University of NebraskaInventor: Sam D. Sanderson
-
Patent number: 7291714Abstract: The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: February 14, 2000Date of Patent: November 6, 2007Assignee: Millennium Pharmaceuticals, Inc.Inventors: Samantha J. Busfield, Jean-Luc Villeval
-
Patent number: 7288634Abstract: The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue. The invention also relates to antibodies against the peptide and a method of detecting autoimmune antibodies.Type: GrantFiled: June 23, 2005Date of Patent: October 30, 2007Assignee: Stichting Voor De Technische WetenschappenInventors: Waltherus J. W. Van Venrooij, Gerardus Antonius Schellekens, Jozef M. H. Raats, Rene M. A. Hoet